| Literature DB >> 31547212 |
Claudia Conte1, Giovanni Dal Poggetto2, Benjamin J Swartzwelter3, Diletta Esposito4, Francesca Ungaro5, Paola Laurienzo6, Diana Boraschi7,8, Fabiana Quaglia9.
Abstract
Nanoparticles (NPs) based on amphiphilic block copolymers of polyethylene glycol (PEG) and biodegradable polyesters are of particular current interest in drug nanodelivery due to their easily manipulated properties. The interaction of these NPs with biological environments is highly influenced by shell features, which drive biological identity after administration. To widen the strategies available for tuning particle surface chemistry, here we developed a panel of amine-bearing PEGylated NPs with a poly(ε-caprolactone) (PCL) core for the delivery of lipophilic drugs, and investigated the impact of NP modifications on their interaction with abundant circulating proteins (human serum albumin-HSA-and mucin), as well as their transport through biological barriers (artificial mucus-AM, extracellular matrix-ECM). We prepared NPs based on a diamino-terminated PCL (amine-NPs) and its mixture with PEG-PCL copolymers (amine/PEG-NPs) at different PEG molecular weights by nanoprecipitation, as well as corresponding NPs of PEG-PCL (PEG-NPs). The presence of an amine-bearing polymer resulted in NPs with a net positive charge and a zeta potential dependent on the length of PEG in the copolymer. Amine/PEG-NPs had a larger fixed aqueous layer thickness as compared to PEG-NPs, suggesting that PEG conformation is affected by the presence of positive charges. In general, amine-bearing NPs promptly interacted with the dysopsonic protein HSA, due to electrostatic interactions, and lose stability, thereby undergoing time-related aggregation. On the other hand, amine/PEG-NPs interaction with mucin induced switching to a negative surface charge but did not alter the quality of the dispersion. The transport kinetics of NPs through a layer of artificial mucus and tumor extracellular matrix was studied by means of fluorescent NPs based upon FRET. Amine/PEG-NPs did not cross the ECM, but they were promptly transported through the AM, with swifter transport noted at increasing MWs of PEG in the copolymer. Finally, we demonstrated that all the different NP types developed in this study are internalized by human monocytes and, despite the positive charge, they did not induce a measurable inflammatory effect. In conclusion, we showed that the concurrent presence of both PEG and amine groups on NP surface is a promising strategy for directing their interaction with body compartments. While PEG-NPs are confirmed for their capacity to cross ECM-like compartments, amine/PEG-NPs are revealed as a powerful platform to widen the arsenal of nanotools available for overcoming mucus-covered epithelia.Entities:
Keywords: PEGylated nanoparticles; biological barriers; cationic nanoparticles; proteins
Year: 2019 PMID: 31547212 PMCID: PMC6835417 DOI: 10.3390/nano9101354
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Figure 1(a) Steps for the synthesis of NH2-PCL-NH2. (b) 1H NMR spectrum of NH2-PCL-NH2 in CDCl3.
Figure 2Schematic representation of nanoparticles tested in the study.
Colloidal properties of NPs. Values are expressed as mean ± SD of three different batches.
| Code | Composition | Yield (%) | Poloxamer 2 (mg) | DH 3 (nm ± SD) | PI 3 | ζ 4 (mV ± SD) | |
|---|---|---|---|---|---|---|---|
| PEG-NPs | PEG1K-NPs | PEG1K-PCL4K | 80 | 2.2 | 78 ± 0.3 | 0.224 | −10.2 ± 2.0 |
| PEG2K-NPs | PEG2K-PCL4K | 95 | 1.3 | 44 ± 1.3 | 0.160 | −17.1 ± 1.6 | |
| PEG5K-NPs | PEG5K-PCL5K | 98 | 1.9 | 44 ± 3.6 | 0.175 | −7.4 ± 1.9 | |
| Amine-NPs | Am-NPs | NH2-PCL4K-NH2 | 82 | - | 134 ± 0.3 | 0.128 | 34.3 ± 1.3 |
| Amine/PEG-NPs 1 | Am/PEG1K-NPs | NH2-PCL4K-NH2k | 93 | 2.4 | 121 ± 2.8 | 0.191 | 28.6 ± 1.0 |
| Am/PEG2K-NPs | NH2-PCL4K-NH2 | 95 | 1.0 | 99 ± 5.9 | 0.257 | 20.0 ± 2.3 | |
| Am/PEG5K-NPs | NH2-PCL4K-NH2 | 98 | 1.2 | 94 ± 6.8 | 0.250 | 21.3 ± 2.4 |
1: Copolymer mixture was 1:1 by wt.; 2: Pluronic® F68 associated to NPs was derived from the amount found in the medium after NPs preparation. Quantitative 1H NMR measurements were taken as described in 2.4.; 3: DH and PI were measured in water by DLS; 4: ζ measures the electrophoretic mobility of NPs.
Figure 3Fixed aqueous layer thickness (FALT) measurements for (a) PEG-NPs and (b) Am/PEG-NPs.
Shell thickness of NPs and percentage of PEG on NPs surface.
| Type | Shell Thickness 1 (nm) | Surface PEG 2 (wt %) |
|---|---|---|
| PEG1K-NPs | 2.5 ± 0.4 | 3 |
| PEG2K-NPs | 3.4 ± 0.8 | 11 |
| PEG5K-NPs | 4.0 ± 0.2 | 5 |
| Am/PEG1K-NPs | 3.5 ± 0.2 | 2 |
| Am/PEG2K-NPs | 6.8 ± 1.2 | 4 |
| Am/PEG5K-NPs | 11.8 ± 0.9 | 2 |
1: Slope of the regression line of FALT analysis in Figure 3; 2: Surface PEG calculated by 1H NMR as described in 2.5.
Figure 4Interaction of NPs with proteins. Fluorescence emission spectra of HSA (0.2 mg/mL) at Ex = 278 nm in the presence of PEG-NPs (a) and Am-NPs or Am/PEG-NPs (b) (NPs = 0.5 mg/mL). Spectrum of free HSA is reported as control. Representative size distribution curves of PEG-NPs (c) and Am-NPs or Am/PEG-NPs (d) incubated in HSA (0.2 mg/mL) (NPs = 0.5 mg/mL).
Figure 5Interaction of NPs with mucin. Scattering of PEG-NPs (a) or Am-NPs and Am/PEG-NPs (b) in water or in a mucin water dispersion (0.08% w/v) (NPs = 0.5 mg/mL). Data are an average of triplicate measurements ± SD. Representative size distribution curves of PEG-NPs (c) or Am-NPs and Am/PEG-NPs (d) in a mucin water dispersion (0.08% w/v) (NPs = 0.5 mg/mL).
Figure 6Permeation of NPs through protein-rich gels over time. For this experiment, NPs were loaded with DiO/DiL as a FRET pair. (a) Emission spectra collected after DiO excitation (λex = 488 nm) of DiO/DiL-loaded PEG5k-NPs dispersed in water or dissolved in DCM. (b) Set-up of the transport experiment. Amount of DiO/DiL-loaded PEG-NPs (c,e) and amine-NPs and amine/PEG-NPs (d,f) found in the acceptor chamber after crossing the ECM gel (c,d) and artificial mucus (e,f). The amount of NPs in the acceptor medium was evaluated by monitoring DiL emission (λex = 543 nm). In the inset, FRET efficiency is reported (for the calculation, see Section 2.7). Data are an average of triplicate measurements ± SD.
Figure 7Uptake and inflammatory response to NPs by human monocytes. (a) Quantification of NPs taken up by monocytes after 2 h incubation. Production of IL-1β (b,c) and TNFα (d,e) by human monocytes after 24 h of incubation with NPs as assessed by an ELISA kit. Panels (c,e) refer to LPS stimulated monocytes. Results represent mean ± SEM, n = 2.